Aurealis Therapeutics

Aurealis Pharma is a Swiss-Nordic Cell and Gene Therapy Platform Company, with a slogan: "Multi-target cell and gene therapies for unmet medical needs." The company focuses on addressing unmet medical needs such as chronic wounds, deadly cancers, and inflammation through its multi-target cell and gene therapy platform, which is based on genetically modified safe lactic acid bacteria. After successfully completing a Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with their lead clinical product AUP-16, the company is currently conducting a Phase 2 study in Italy, Germany, and Poland. The focus will then shift to Venous Ulcers and other ulcers. In the oncology field, Aurealis Pharma is building on impressive pre-clinical data with their lead candidate AUP-55, showing increased survival rates in Ovarian Cancer and peritoneal carcinomatosis. The company's pipeline also includes inflammation, which is at the discovery stage. Aurealis Pharma received a $10.00M Series A investment on 30 March 2023, from investors including Tesi, Lynx Capital, and Zhejiang Huahai Pharmaceutical. The company, founded in 2010, operates in the Biotechnology and Pharmaceutical industries.